Aflatoxin B1 is a carcinogen produced by Aspergillus flavus and a few related fungi that are often present in many food substances. It interacts synergistically with Hepatitis B or C virus (HBV, HBC) infection, thereby increasing the risk of hepatocellular carcinoma (HCC). The G to T transversion at the third position of codon 249 (AGG) of the TP53 gene, substituting arginine to serine, is the most common aflatoxin-induced mutation linked to HCC. This study examined
Introduction
Hepatocellular carcinoma (HCC) is the sixth most common cancer in the world, accounting for about 5% of all human cancers, and the second cause of death from cancer worldwide [1] . It is the fifth most common cancer in men and the eighth most common cancer in women [2] . The incidence of HCC in India is reported to be between 0.2 and 1.9% [3] . Infection with hepatitis B or C virus is considered to be the major cause for HCC. The hepatitis B virus (HBV) is highly prevalent in the developing world, with an estimated two billion people infected. In India, HBV prevalence among the general population ranges from 2% to 8%, placing India in the intermediate HBV-endemic zone, where the number of HBV carriers is estimated to be 50 million, forming the second largest global pool of chronic HBV infections [4] . Previous studies have implicated a multifaceted etiology for human HCC [5] . In addition to chronic infection with hepatitis B or C viruses and lifestyle habits (such as alcohol abuse), dietary exposure to aflatoxin B1 (AFB1) is a major risk factor for development of human HCC [5] [6] , especially where exposure to HBV is endemic.
Mycotoxins are toxins produced by certain fungi, and aflatoxins are an important group of mycotoxins produced by the fungi Aspergillus flavus and A. parasiticus, which contaminate staple foods including groundnuts [2] . The etiologic involvement of AFB1 in human HCC can be inferred from the high incidence of this disease in certain geographical regions, particularly, South and Southeast Asia and sub-Saharan Africa, where the warm and humid climate promotes mold growth and contamination of food supplies by this naturally occurring mycotoxin [5] [6] .
Several studies have shown that aflatoxin contamination is frequent in food crops grown in Asia and sub-Saharan Africa [7] . AFB1 is metabolized by P450 enzymes in the liver and generates an epoxide that is highly reactive with DNA, forming adducts at the N7 position of guanine. If not repaired, these lesions may lead to permanent DNA mutations, preferentially G to T transversions [2] . The epoxides are detoxified to a limited extent by glutathione S-transferase (GST)-mediated conjugation with reduced glutathione (GSH) to form AFB1 exo-and endoepoxide-GSH conjugates [8] . The most common aflatoxin-induced mutational hot spot found in HCCs in more than 50% of cases reported from different geographical regions, such as China and southern Africa, is a G to T transversion at the third position of codon 249 (AGG) of the TP53 gene, which results in the substitution of arginine by serine [1, 9] . However, very little is known about the prevalence of aflatoxin exposure and its impact on liver disorders in HBV-M a n u s c r i p t 4 positive patients in India. Earlier reports on liver-biopsy samples suggest that the frequency of TP53 mutation is low in India [10] . Another study measured AFB1 exposure in 4.5% of HBVpositive samples in India [11] .
This study was undertaken to determine the association between infection with HBV, exposure to aflatoxin, and mutation in codon 249 of TP53, in blood samples of patients with different stages of liver disease. This work is based on a model for end-stage liver disease (MELD) in 130 subjects positive for HBV and/or suffering from liver cirrhosis, and 108 samples from a healthy control group (hepatitis B-or C-negative, no liver disorder).
Materials and methods

Sample collection
Samples were collected from two hospitals in Hyderabad during the years 2009 and 2010.
Patients with clinically confirmed liver disorders (decompensated liver disease) were selected for this study. A total of 238 blood samples were collected, of which 130 blood samples were from patients with liver diseases, and 108 samples were from the control group comprising individuals living in the same household as the diseased subject, but without any history of liver disease. (MELD) and 'Child Turcotte Pugh' (CTP) scoring systems [12] . All the objectives of the study were clearly explained to the participating individuals, and written consent was obtained before collecting blood samples. The study was approved by the Ethics Committee of the Nizam's Institute of Medical Sciences, Hyderabad. The CTP scoring-system involves allotting points for albumin level, ascites, total bilirubin, prothrombin time and hepatic encephalopathy, and scores can vary from 5-15 (Table 1 ). Based on total score, patients are designated as Child's class A (CTP 5-6), class B (CTP 7-10) and class C (CTP 11-15).
Scoring the severity of liver disease based on clinical profile
Detection of TP53 mutation by PCR amplification and restriction-enzyme digestion
DNA was extracted from blood samples that were taken from the subjects and collected in EDTA vials. Samples were kept in an ice-box and transferred to the Mycotoxicology and Virology lab at ICRISAT, Hyderabad, where they were stored at -20ºC until processing time.
DNA was extracted from 200 µl of blood by use of a commercial DNA-extraction kit (Nucleospin Blood, Cat # 740951, Macherey Nagel, Germany) according to the manufacturer's protocol. DNA was used for the amplification of a 254-bp portion of exon 7 surrounding codon 249 by means of the polymerase chain-reaction (PCR) with primer pair p53Fser (5'CTT GCC ACA GGT CTC CCC AA 3') and p53Rser (5'AGG GGT CAG RGG CAA GCA GA 3'), similar to the primers used in earlier work in China [14] . PCR was performed in a thermal cycler (Applied Biosystems) with an initial denaturation step of 2 min at 94°C followed by 40 cycles of denaturation at 94°C for 30 seconds (s), annealing at 60°C for 30s, and extension at 72°C for 30s. The amplified product (6 µl) was digested with restriction enzyme Hae III (New England Biolabs, UK) at 37˚C for 4 h. PCR products and Hae III-digested products were analyzed by means of electrophoresis in a 2% TAE-agarose gel. The gels were stained with ethidium bromide and visualized on a UV-transilluminator.
Measurement of aflatoxin-albumin adducts
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A c c e p t e d M a n u s c r i p t 6 The AFB1-lysine (AFB1-lys) adduct found in human serum-albumin (HSA) was used as a biomarker to assess exposure to aflatoxin of the subjects [11] . Five ml of blood sample were collected in plain vacutainers from 238 individuals. Serum was separated from each sample and processed to measure the amount of AFB1-lys adduct by an indirect competitive enzyme-linked immunosorbent assay (IC-ELISA) essentially as described by Anitha et al. [11] . This procedure involves extraction of the albumin fraction from 500 µl of serum, and measurement of its concentration according to Bradford [15] . Two mg of albumin was digested with proteinase K, and the digested product was analyzed in an IC-ELISA with an antibody produced against AFB1-BSA conjugate [11] . Alkaline phosphatase-conjugated anti-rabbit antibodies (AR-ALP) were used as a secondary antibody, and p-nitrophenyl phosphate (pNPP) was applied as a substrate. The colorimetric reaction was followed on an ELISA plate-reader with a 405-nm filter.
Statistical Analysis
Samples were collected from 238 individuals with clinical profiles, food (diet) consumptionrelated questionnaires and demographic data. These data were entered in a database (SAS 9.2V) and used for statistical analysis with SAS 9.2V. Pearson's chi-square and Fisher's exact tests were applied to assess the statistical significance of the frequency of independent variables and codon-249Ser mutations, by means of the software SAS 9.2V. This helped to estimate the risk of mutation among the study groups considering age, sex, HBV surface-antigen status, and aflatoxin-exposure status as potential confounders.
Results
A total of 238 blood samples were analyzed for the presence of TP53 gene mutations.
The age of the subjects (64% men) ranged from 36 to 61 years, 130 individuals were HBVpositive and 108 negative. Among the HBV-positive samples, 112 were from subjects with liver cirrhosis. The use of PCR primers p53Fser and p53Rser resulted in amplification of a 254-bp product in all 238 samples (Fig. 1) . The presence of a mutation in codon 249 was assessed by RFLP of the PCR product, by use of the Hae III enzyme that cleaves the GG ↓ CC sequence at codon position 249-250, generating products of 92 bp, 66 bp and several smaller fragments from M a n u s c r i p t 7 the 254-bp PCR product. In samples with a G→T mutation at codon 249, Hae III digestion yields a 158-bp fragment due to loss of a restriction site (Fig. 1) .
The G→T mutation at codon 249 of the TP53 gene was detected in 10 samples (4.2%), eight of which were from subjects infected with HBV and suffering from liver cirrhosis, and who also had aflatoxin-albumin adduct (p = 0.07); the other two were from control subjects (HBVnegative, no liver disease) who were positive for the AFB1-1ys adduct (p = 0.14). In 37 of 238 samples analyzed, the AFB1-lys adduct was found in the IC-ELISA. Among these, 29 samples were from subjects who had cirrhosis of the liver and were positive for HBV, and eight samples were from individuals who were positive for both HBV and mutation in TP53 (p=0.07).
Of ten samples positive for mutation at codon 249 of TP53, two were from the control group, five samples were in the Child-B and three in the Child-C category, with the highest MELD scores with decompensated liver disease ( Table 2 ). These ten samples also had a high amount of AFB1-lys adducts (>76 pg/mg albumin) ( Table 3) . With a set p-value of 0.1, aflatoxin exposure (AFB1-lys) and TP53 mutation were dependent on each other, otherwise they were independent (Table 4 ). This shows that TP53 mutation and AFB1-lys adduct are dependent in Table 2 ).
There was no significant difference in the 249Ser mutation level between females with HBV (p=0.12) and males with HBV (p=0.38). This shows that sex has no influence on the presence of aflatoxin and TP53 mutation. Similarly, daily consumption of rice and the presence of AFB1-lys with TP53 mutation in HBV-positive individuals had no significant influence (p=0.19). With a set p-value of 0.1, the influence of aflatoxin exposure and TP53 mutation in non-alcoholic individuals with liver disease and HBV-positive status were dependent on each other, otherwise they were independent (p=0.05) ( Table 4 ). The concentration of the AFB1-lys adduct ranged from 2.5 to 677 pg/mg albumin with a mean adduct level of 52.1 pg/mg.
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A c c e p t e d M a n u s c r i p t 8 Interestingly, the individuals positive for both HBV and TP53 mutation had an AFB1-lys level > 75 pg/mg albumin (Table 3 ). This level was higher than that of individuals positive for HBV and without mutation (< 75 pg/mg albumin). The MELD score showed that the presence of HBV together with AFB1-lys produced a higher mutation percentage, and all patients had decompensated liver disease (Table 2 ).
Discussion
Carcinogenesis is a multistep process, and the interaction of host-cell factors along with viral and chemical carcinogens appears to play a key role in the development of hepatocellular carcinoma in humans [10] . When the liver is exposed to HBV, the hepatocytes are injured and undergo structural changes [15] . Dietary exposure to AFB1 leads to the formation of aflatoxin epoxide, which is highly reactive and binds to albumin, which is a major plasma protein produced in liver cells. It also binds to DNA, forming adducts at the N7 position of guanine [16] [17] . A lack of repair may give rise to mutations in the TP53 gene, which may lead to the loss of its tumour-suppressor function and uncontrolled proliferation of liver cells, which may result in HCC. The transformation of a normal cell to a cancercell is a complex process, accompanied by multiple steps of genetic and epigenetic alterations [18] . Although a diverse set of genes has been implicated in tumorigenesis, the transcription factor p53 (encoded by the human gene TP53) stands out as a key tumour-suppressor gene [19] . The role of TP53 as a tumour-suppressor gene includes the ability to induce cell cycle arrest, DNA repair, senescence, and apoptosis [20] . The TP53 gene in human tumours is often found to undergo missense mutation, where a single nucleotide is substituted with another [21] . Consequently, a full-length protein containing only a single amino-acid substitution is produced, which results in loss of its suppressor activity. It is well established that p53 inactivation and expression of mutant p53 can confer cells with additive growth and survival advantages, such as increased proliferation, evasion of apoptosis, and chemo-resistance [18] .
Globally, 600,000 people die every year due to infection with Hepatitis B [22] . In the Middle-East and on the Indian sub-continent, 2-5% of the general population is chronically infected with Hepatitis B virus [22] . In India, few studies previously indicated that AFB1 exposure is one of the important and possible risks for liver cancers [23] . However no study has been conducted in India to map the associations among aflatoxin exposure, TP53 mutations and A c c e p t e d M a n u s c r i p t 9 liver diseases in tandem. In our study, we made an attempt to look into these complex relationships. Surprisingly, of 238 patients analyzed, 10 patients were positive for TP53 mutation, and all of them were positive for AFB1-lys, an indication of aflatoxin exposure.
Frequencies of aflatoxin exposure, TP53 mutation and HBV, with p-values in the Chi-square test and in Fisher's exact test were analysed (Table 4 ). There were eight samples from individuals with high aflatoxin exposure (protein adduct level >76 pg/mg albumin) and TP53 mutation and two samples from subjects with low aflatoxin-protein levels (<76 pg/mg albumin) ( Table 3 ).
This shows that the level of AFB1-lys may raise the probability of obtaining a TP53 mutation.
Although the number of mutations is low, it is still considerable when taking 138 cirrhosis samples into consideration. In the study group, 216 individuals were non-alcoholic. Among them, 23 HBV-positive individuals had the AFB1-lys adduct in their blood and eight of them had a TP53 mutation (p=0.05) ( Table 4) . Among the 22 alcoholics, not one had a TP53 mutation.
These data indicate a link between the occurrence of a mutation at codon 249 with the presence of aflatoxin-albumin adduct in blood, which is an indication of exposure to dietary aflatoxins.
No significant correlation was observed between consumption of rice and the presence of aflatoxin-albumin adducts with TP53 mutation (Table 4) . People in southern India consume diverse foods apart from rice (corn, wheat, chillies and groundnuts) every day. This may have a cumulative effect on the presence of aflatoxin-albumin adduct in the blood. It is difficult to determine the exact contributing dietary source of aflatoxin unless the foods themselves are analyzed for aflatoxin.
The results of the present study show an association between HBV and AFB1 in patients with liver disorders. An earlier study conducted in India [10] on TP53 tumour-suppressor gene mutations in 21 patients with HCC, revealed a low frequency (9.5%; 95% CI, 22.1 -23.0) of TP53 gene mutation at codon 249, the most common mutational hot spot in HCC. A low frequency of TP53 mutation involving codon 249 has also been reported in Germany, Taiwan, and Thailand [24] [25] [26] . The levels of dietary exposure to aflatoxin in Thailand and the presence of the mutated DNA in plasma is consistent with the notion that exposure to this toxin, together with chronic HBV infection remains a major etiological factor for HCC in Thailand [2] . The aflatoxin level in India was high in non-carriers of HBV, which is indicative of the independent role played by AFB1 in hepatocarcinogenesis [3] . With 68.7% of the non-B non-C hepatitis M a n u s c r i p t 10 patients having tissue localization of AFB1, and the concomitant presence of AFB1 along with HBV in 46.1% of cases studied, HBV is an additional risk factor to which populations from developing countries are exposed, and it plays an aggravating role in hepatocarcinogenesis. This statement is supported by the current study in which 22% of HBV-positive cases had aflatoxinalbumin adduct, of which 8% had a TP53 mutation. Interestingly, 7.4 % of individuals in the healthy control group (HBV-negative, no liver disease) had the aflatoxin-albumin adduct and 1.8% of these had a TP53 mutation, with a high aflatoxin-albumin level, ranging between 300-600 pg/mg albumin.
The MELD and CTP scores were used to identify the severity of liver disease. MELD and CTP scores are complementary to each other in evaluating the progressive clinical condition of liver cirrhosis [27] . They also provide the advantage of ranking patients according to the severity of the underlying liver disease and risk of mortality [12] is an indication for liver transplantation or mortality [12] . The data show that most of the endstage liver disease and CTP scores are linked with the presence of aflatoxin and HBV, which Page 11 of 19 A c c e p t e d M a n u s c r i p t 11 indicates that these two together increase the severity of the liver disease. Finally, on the one hand it is very important to have good biomarker system for the detection of aflatoxin exposure and its deleterious effects on human health. On the other hand, it is always important to raise the awareness levels among different stakeholders and to have proper regulatory limits to restrict the free allowance of aflatoxin-contaminated products into the food chain. The proper management of controlling aflatoxin exposure at an early stage would help reduce the chance of getting a TP53 mutation, and the patient would respond to the treatment to reduce the viral load to reduce the severity of the liver disease.
Conclusions
This study compared 238 individuals with (130 HBV-positive) or without liver disease (108 
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